Recombinant Anti-CD28 x Anti-HN Bispecific Antibody (scIgG) (SCIGG-061)

Recombinant Anti-CD28 x Anti-HN Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD28 and anti-HN IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can retarget T cells to tumor cells. It is designed for the tumor vaccine modification and the research of Tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD28 & HN

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising preventive/therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Target 2

Gene ID

912270

UniProt ID

Q9Q2W5

Alternative Names

Hemagglutinin-neuraminidase; HN

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD28 x Anti-HN Bispecific Antibody (scIgG) (SCIGG-061). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD28 x Anti-HN Bispecific Antibody (scIgG) (CAT#: SCIGG-061)

Specifications

Targets

Customer Reviews and Q&As